These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34624769)

  • 1. Early factors for predicting discontinuation to subcutaneous Apomorphine infusion in Parkinson's disease: A prospective analysis of the Thai Apomorphine Registry.
    Phokaewvarangkul O; Anan C; Phimpha A; Chaudhuri KR; van Laar T; Bhidayasiri R
    Parkinsonism Relat Disord; 2021 Oct; 91():146-151. PubMed ID: 34624769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study.
    García Ruiz PJ; Sesar Ignacio A; Ares Pensado B; Castro García A; Alonso Frech F; Alvarez López M; Arbelo González J; Baiges Octavio J; Burguera Hernández JA; Calopa Garriga M; Campos Blanco D; Castaño García B; Carballo Cordero M; Chacón Peña J; Espino Ibáñez A; Gorospe Onisalde A; Giménez-Roldán S; Granés Ibáñez P; Hernández Vara J; Ibáñez Alonso R; Jiménez Jiménez FJ; Krupinski J; Kulisevsky Bojarsky J; Legarda Ramírez I; Lezcano García E; Martínez-Castrillo JC; Mateo González D; Miquel Rodríguez F; Mir P; Muñoz Fargas E; Obeso Inchausti J; Olivares Romero J; Olivé Plana J; Otermin Vallejo P; Pascual Sedano B; Pérez de Colosía Rama V; Pérez López-Fraile I; Planas Comes A; Puente Periz V; Rodríguez Oroz MC; Sevillano García D; Solís Pérez P; Suárez Muñoz J; Vaamonde Gamo J; Valero Merino C; Valldeoriola Serra F; Velázquez Pérez JM; Yáñez Baña R; Zamarbide Capdepon I
    Mov Disord; 2008 Jun; 23(8):1130-6. PubMed ID: 18442107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous subcutaneous apomorphine infusion in Parkinson's disease: causes of discontinuation and subsequent treatment strategies.
    Olivola E; Fasano A; Varanese S; Lena F; Santilli M; Femiano C; Centonze D; Modugno N
    Neurol Sci; 2019 Sep; 40(9):1917-1923. PubMed ID: 31111272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of continuous subcutaneous apomorphine infusion in Parkinson's disease without cognitive impairment on motor, cognitive, psychiatric symptoms and quality of life.
    Houvenaghel JF; Drapier S; Duprez J; Robert GH; Riou A; Drapier D; Sauleau P; Vérin M
    J Neurol Sci; 2018 Dec; 395():113-118. PubMed ID: 30312901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous Subcutaneous Infusion Delivery of Apomorphine in Parkinson's Disease: A Systematic Review.
    Kukkle PL; Garg D; Merello M
    Mov Disord Clin Pract; 2023 Sep; 10(9):1253-1267. PubMed ID: 37772305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Caregiver burden and its related factors in advanced Parkinson's disease: data from the PREDICT study.
    Tessitore A; Marano P; Modugno N; Pontieri FE; Tambasco N; Canesi M; Latorre A; Lopiano L; Sensi M; Quatrale R; Solla P; Defazio G; Melzi G; Costanzo AM; Gualberti G; di Luzio Paparatti U; Antonini A
    J Neurol; 2018 May; 265(5):1124-1137. PubMed ID: 29516169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial.
    Katzenschlager R; Poewe W; Rascol O; Trenkwalder C; Deuschl G; Chaudhuri KR; Henriksen T; van Laar T; Spivey K; Vel S; Staines H; Lees A
    Lancet Neurol; 2018 Sep; 17(9):749-759. PubMed ID: 30055903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term Apomorphine Infusion Users Versus Short-term Users: An International Dual-center Analysis of the Reasons for Discontinuing Therapy.
    Bhidayasiri R; Phokaewvarangkul O; Boonpang K; Boonmongkol T; Thongchuem Y; Kantachadvanich N; García Ruiz PJ
    Clin Neuropharmacol; 2019; 42(5):172-178. PubMed ID: 31567642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of subcutaneous infusion of apomorphine in Parkinson's disease.
    Wenzel K; Homann CN; Fabbrini G; Colosimo C
    Expert Rev Neurother; 2014 Jul; 14(7):833-43. PubMed ID: 24917215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of life in Parkinson's disease improved by apomorphine pump: the OPTIPUMP cohort study.
    Drapier S; Eusebio A; Degos B; Vérin M; Durif F; Azulay JP; Viallet F; Rouaud T; Moreau C; Defebvre L; Fraix V; Tranchant C; Andre K; Courbon CB; Roze E; Devos D
    J Neurol; 2016 Jun; 263(6):1111-9. PubMed ID: 27060084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous subcutaneous apomorphine infusion in Parkinson's disease patients with cognitive dysfunction: A retrospective long-term follow-up study.
    Borgemeester RWK; van Laar T
    Parkinsonism Relat Disord; 2017 Dec; 45():33-38. PubMed ID: 29032012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D; Hanssens Y; Northway MG
    Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Motor and non-motor outcomes of continuous apomorphine infusion in 125 Parkinson's disease patients.
    Borgemeester RW; Drent M; van Laar T
    Parkinsonism Relat Disord; 2016 Feb; 23():17-22. PubMed ID: 26709292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Continuous subcutaneous infusion of apomorphine in Parkinson's disease: retrospective analysis of a series of 81 patients].
    Rambour M; Moreau C; Salleron J; Devos D; Kreisler A; Mutez E; Simonin C; Annic A; Dujardin K; Destée A; Defebvre L
    Rev Neurol (Paris); 2014 Mar; 170(3):205-15. PubMed ID: 24594365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation.
    Antonini A; Isaias IU; Rodolfi G; Landi A; Natuzzi F; Siri C; Pezzoli G
    J Neurol; 2011 Apr; 258(4):579-85. PubMed ID: 20972684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Motor features and response to oral levodopa in patients with Parkinson's disease under continuous dopaminergic infusion or deep brain stimulation.
    Elia AE; Dollenz C; Soliveri P; Albanese A
    Eur J Neurol; 2012 Jan; 19(1):76-83. PubMed ID: 21645174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Persistence and Monotherapy with Device-Aided Therapies: A Retrospective Analysis of an Israeli Cohort of Patients with Advanced Parkinson's Disease.
    Thaler A; Barer Y; Gross R; Cohen R; Bergmann L; Jalundhwala YJ; Giladi N; Chodick G; Shalev V; Gurevich T
    Adv Ther; 2022 May; 39(5):2009-2024. PubMed ID: 35247187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Shifting to subcutaneous infusion of apomorphine in advanced Parkinson's disease patients on an out-patient basis: experience and recommendations].
    Castaño B; Mateo D; Giménez-Roldán S
    Neurologia; 2007 Apr; 22(3):133-7. PubMed ID: 17364250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
    Manson AJ; Turner K; Lees AJ
    Mov Disord; 2002 Nov; 17(6):1235-41. PubMed ID: 12465062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility and benefits of home initiation of subcutaneous apomorphine infusion for patients with Parkinson's disease: the APOKADO study.
    Zagnoli F; Leblanc A; Viakhireva-Dovganyuk I; Delabrousse-Mayoux JP; Pouyet A; Ziegler M; Sogni L; Patat M; Bouillot R; Vérin M;
    J Neural Transm (Vienna); 2023 Nov; 130(11):1463-1474. PubMed ID: 36862190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.